Triple threat: new drug cocktail aims to wipe out CLL/SLL
NCT ID NCT07582159
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and tafasitamab—in 35 people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this mix is safe and can lead to a complete response with very low levels of remaining cancer cells. The drugs work by blocking key proteins that help cancer cells survive and by helping the immune system attack them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib, venetoclax, and tafasitamab
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for CLL/SLL, potentially leading to deeper remissions without the need for continuous therapy.
- What could go wrong
- This is an early phase 2 trial with only 35 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it will outperform existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?